5-[(2,6-difluoro-benzoyl)-(4-methoxy-benzyl)-amino]-thiazole-4-carboxylic acid | 874288-83-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[(2,6-difluoro-benzoyl)-(4-methoxy-benzyl)-amino]-thiazole-4-carboxylic acid
• 英文别名: 5-[(2,6-difluorobenzoyl)-[(4-methoxyphenyl)methyl]amino]-1,3-thiazole-4-carboxylic acid
• CAS: 874288-83-2
• 化学式: C₁₉H₁₄F₂N₂O₄S
• 分子量: 404.394
• InChiKey: VTRCIAWOCALATC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-[(2,6-difluoro-benzoyl)-(4-methoxy-benzyl)-amino]-thiazole-4-carboxylic acid 、 1-Boc-4-氨基哌啶 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以90%的产率得到4-({5-[(2,6-difluoro-benzoyl)-(4-methoxy-benzyl)-amino]-thiazole-4-carbonyl}-amino)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  [FR] COMPOSES PHARMACEUTIQUES

  摘要：

  公开号：

  WO2006008545A3
• 作为产物：
  描述：

  5-[(2,6-difluoro-benzoyl)-(4-methoxy-benzyl)-amino]-thiazole-4-carboxylic acid ethyl ester 在 sodium hydroxide 、 乙醇 、 水 、 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 24.0h， 以92%的产率得到5-[(2,6-difluoro-benzoyl)-(4-methoxy-benzyl)-amino]-thiazole-4-carboxylic acid
  参考文献：
  名称：

  [EN] THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  [FR] COMPOSES PHARMACEUTIQUES

  摘要：

  公开号：

  WO2006008545A3

文献信息

• Pharmaceutical Compounds
  申请人：Berdini Valerio

  公开号：US20080167309A1

  公开（公告）日：2008-07-10

  The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase, the compound having the formula (I): and salts, tautomers, N-oxides or solvates thereof, wherein A is a bond, C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; Q is S or CR 2 ; J is S or CH; provided that one of Q and J is S, and the other of Q and J is not S; when Q is S, there is a double bond between the ring carbon atoms “a” and “b” and a double bond between the ring nitrogen N and J; and when J is S, there is a double bond between Q and the ring carbon atom “a” and a double bond between the ring nitrogen N and the ring carbon atom “b”; and R 1 to R 4 are as defined in the claims.

  本发明提供了一种化合物，用于预防或治疗由细胞周期依赖性激酶介导的疾病状态或病症，该化合物具有以下式子（I）和其盐、互变异构体、N-氧化物或溶剂化物：其中，A是键合、C═O、NRg(C═O)或O(C═O)，其中Rg为氢或C1-4烃基，可选地被羟基或C1-4烷氧基取代；Y是长度为1、2或3个碳原子的烷基链或键合；Q是S或CR2；J是S或CH；前提是Q和J中的一个是S，而另一个不是S；当Q是S时，环上碳原子“a”和“b”之间有双键，环氮原子N和J之间也有双键；当J是S时，Q和环上碳原子“a”之间有双键，环氮原子N和环上碳原子“b”之间也有双键；R1至R4如权利要求所定义。
• Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
  申请人：Berdini Valerio

  公开号：US20080312223A1

  公开（公告）日：2008-12-18

  The invention provides a compound of the formula (I): or a salt, N-oxide, tautomer or solvate thereof, wherein X is CR 5 or N; each of Q 1 and Q 2 is a carbon atom; Q 3 is selected from S and CH; Q 4 is selected from CR 2 and S; provided that one of Q 3 and Q 4 is S and the other of Q 3 and Q 4 is not S; wherein when Q 3 is S, there is a double bond between Q 1 and Q 4 and a double bond between Q 2 and the adjacent ring nitrogen atom N; and when Q 4 is S, there is a double bond between Q 1 and Q 2 , and a double bond between Q 3 and the adjacent ring nitrogen atom N; A is a bond or —(CH 2 ) m —(B) n —; B is C═O, NR 8 (C═O) or O(C═O) wherein R 1 is hydrogen or C1_4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R o is hydrogen or, together with NR g when present, forms a group —(CH 2 ) p — wherein p is 2 to 4; R 1 is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C 1-8 hydrocarbyl group; R 2 is hydrogen, halogen, methoxy, or a C 1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy; R 3 and R 4 together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; and R 5 is hydrogen, a group R 2 or a group R 10 wherein R 10 is as defined in the claims. The compounds have activity as inhibitors of cyclin dependent kinases, glycogen synthase kinases and Aurora kinases.

  本发明提供一种化合物，其化学式为（I）或其盐，N-氧化物，互变异构体或溶剂化物，其中X为CR5或N; Q1和Q2中的每一个都是碳原子; Q3从S和CH中选择; Q4从CR2和S中选择; 假设Q3和Q4中的一个是S，而另一个不是S; 当Q3为S时，Q1和Q4之间有一个双键，Q2和相邻的环氮原子N之间有一个双键; 当Q4为S时，Q1和Q2之间有一个双键，并且Q3和相邻的环氮原子N之间有一个双键; A是键或-(CH2)m-(B)n-; B为C═O，NR8（C═O）或O（C═O），其中R1为氢或C1_4烃基，可选择地被羟基或C1-4烷氧基取代; m为0、1或2; n为0或1; Ro为氢或与NRg一起形成一个群体-(CH2)p-，其中p为2至4; R1为氢，具有3至12个环成员的碳环或杂环基，或可选择地被取代的C1-8烃基基团; R2为氢、卤素、甲氧基或可选择地被卤素、羟基或甲氧基取代的C1-4烃基基团; R3和R4与它们所连接的碳原子一起形成一个可选择地取代的融合碳环或杂环环，其具有5至7个环成员，其中最多可有3个异原子，选择自N、O和S; R5为氢、R2基团或R10基团，其中R10如权利要求所定义。该化合物具有作为细胞周期依赖性激酶、糖原合成酶激酶和极化子激酶的抑制剂的活性。
• THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：Astex Therapeutics Limited

  公开号：EP1781647A2

  公开（公告）日：2007-05-09
• THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES
  申请人：Astex Therapeutics Limited

  公开号：EP1836199A1

  公开（公告）日：2007-09-26
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2006008545A2

  公开（公告）日：2006-01-26

  The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase, the compound having the formula (I): (I) and salts, tautomers, N-oxides or solvates thereof; wherein A is a bond, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; Q is S or CR2; J is S or CH; provided that one of Q and J is S, and the other of Q and J is not S; when Q is S, there is a double bond between the ring carbon atoms “a” and “b” and a double bond between the ring nitrogen N and J; and when J is S, there is a double bond between Q and the ring carbon atom “a” and a double bond between the ring nitrogen N and the ring carbon atom “b”; and R1 to R4 are as defined in the claims.